Inclusion Criteria

Prior Medication:

Allowed:

• Oral nonabsorbable antifungal agents.

The study will include 18 patients with AIDS or HIV-related symptomatic illness as defined by the CDC classification group IVa and c2. Of these, 9 methadone recipients will have been maintained on methadone for at least 1 month and will have received a constant daily dose of 30-90 mg of methadone for at least 10 days.

Nine patients will be former intravenous drug abusers.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

• Temperature > 101 degrees F.
• Ascites.
• Active opportunistic infection.

Concurrent Medication:

Excluded:

• Other inducers or inhibitors of hepatic microsomal enzymes.
• Any chronic systemic medications.

Patients with the following symptoms or conditions are excluded:

• Temperature > 101 degrees F.
• Ascites.
• Active opportunistic infection.

Prior Medication:

Excluded within 72 hours of study entry:

• All medication except oral nonabsorbable antifungal agents.
• Excluded within 2 weeks of study entry:
• Any other experimental drug.
• Drugs with known nephrotoxic potential or drugs known to cause neutropenia.
• Rifampin or its derivatives, phenytoin, or barbiturates.

Active drug or alcohol abuse.